The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

High-throughput methods to investigate tumour omic landscapes have quickly catapulted
cancer specialists into the precision oncology era. The singular lesson of precision oncology …

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

Background Hepatocellular carcinoma (HCC), the third most prevalent cause of cancer-
related death, is a frequent primary liver cancer with a high rate of morbidity and mortality. T …

Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in
predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess …

Despite the promising advances in novel cancer therapy such as immune checkpoint
inhibitors (ICIs), limitations including therapeutic resistance and toxicity remain. In recent …

Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by extensive
intra-tumoral heterogeneity, and frequently develops resistance to therapies. Tumor …

In the past period, due to the rapid development of next-generation sequencing technology,
accumulating evidence has clarified the complex role of the human microbiota in the …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Recent identification of oncogenic cells within healthy tissues and the prevalence of indolent
cancers found incidentally at autopsies reveal a greater complexity in tumor initiation than …